CR2 | Complement component (3d/Epstein Barr virus) receptor 2 | CD markers Disease related genes Plasma proteins Predicted membrane proteins
| | | | | Group enriched |
MS4A1 | Membrane-spanning 4-domains, subfamily A, member 1 | CD markers Disease related genes FDA approved drug targets Predicted intracellular proteins Predicted membrane proteins Transporters
| | | | | Group enriched |
MEF2B | Myocyte enhancer factor 2B | Predicted intracellular proteins Transcription factors
| | | | | Group enriched |
FCRLA | Fc receptor-like A | Predicted intracellular proteins Predicted membrane proteins Predicted secreted proteins
| | | | | Group enriched |
MCEMP1 | Mast cell-expressed membrane protein 1 | Predicted membrane proteins
| | | | | Group enriched |
CD19 | CD19 molecule | CD markers Disease related genes Predicted membrane proteins
| | | | | Group enriched |
FCER2 | Fc fragment of IgE, low affinity II, receptor for (CD23) | Cancer-related genes CD markers Predicted intracellular proteins Predicted membrane proteins
| | | | | Group enriched |
P2RX5 | Purinergic receptor P2X, ligand-gated ion channel, 5 | Predicted intracellular proteins Predicted membrane proteins
| | | | | Group enriched |
DRD5 | Dopamine receptor D5 | Disease related genes FDA approved drug targets G-protein coupled receptors Predicted membrane proteins
| | | | | Group enriched |
TNFRSF13C | Tumor necrosis factor receptor superfamily, member 13C | CD markers Disease related genes Predicted membrane proteins
| | | | | Group enriched |
CD72 | CD72 molecule | CD markers Predicted intracellular proteins Predicted membrane proteins
| | | | | Group enriched |
BTLA | B and T lymphocyte associated | CD markers Predicted intracellular proteins Predicted membrane proteins
| | | | | Group enriched |
FCN1 | Ficolin (collagen/fibrinogen domain containing) 1 | Plasma proteins Predicted membrane proteins Predicted secreted proteins
| | | | | Group enriched |
BANK1 | B-cell scaffold protein with ankyrin repeats 1 | Disease related genes Predicted intracellular proteins
| | | | | Group enriched |
CCR7 | Chemokine (C-C motif) receptor 7 | Cancer-related genes CD markers G-protein coupled receptors Predicted membrane proteins
| | | | | Group enriched |
CXCR5 | Chemokine (C-X-C motif) receptor 5 | CD markers G-protein coupled receptors Predicted membrane proteins
| | | | | Group enriched |
POU2F2 | POU class 2 homeobox 2 | Cancer-related genes Predicted intracellular proteins Transcription factors
| | | | | Group enriched |
SP140 | SP140 nuclear body protein | Predicted intracellular proteins Transcription factors
| | | | | Group enriched |
VIP | Vasoactive intestinal peptide | Cancer-related genes Predicted intracellular proteins Predicted secreted proteins
| | | | | Group enriched |
CD80 | CD80 molecule | CD markers FDA approved drug targets Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
CR1 | Complement component (3b/4b) receptor 1 (Knops blood group) | Blood group antigen proteins CD markers Plasma proteins Predicted membrane proteins
| | | | | Tissue enhanced |
CSF3R | Colony stimulating factor 3 receptor (granulocyte) | Cancer-related genes CD markers Disease related genes FDA approved drug targets Predicted intracellular proteins Predicted membrane proteins
| | | | | Tissue enhanced |
CXCR2 | Chemokine (C-X-C motif) receptor 2 | Cancer-related genes CD markers G-protein coupled receptors Predicted intracellular proteins Predicted membrane proteins
| | | | | Tissue enhanced |
FOXP3 | Forkhead box P3 | Disease related genes Predicted intracellular proteins Transcription factors
| | | | | Tissue enhanced |
FYB | FYN binding protein | Predicted intracellular proteins
| | | | | Tissue enhanced |
GAL | Galanin/GMAP prepropeptide | Plasma proteins Predicted secreted proteins
| | | | | Tissue enhanced |
IL4I1 | Interleukin 4 induced 1 | Enzymes Predicted secreted proteins
| | | | | Tissue enhanced |
ITGAX | Integrin, alpha X (complement component 3 receptor 4 subunit) | CD markers Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
JAK3 | Janus kinase 3 | Cancer-related genes Cytoskeleton related proteins Disease related genes Enzymes FDA approved drug targets Predicted intracellular proteins
| | | | | Tissue enhanced |
MARCO | Macrophage receptor with collagenous structure | Plasma proteins Predicted intracellular proteins Predicted membrane proteins
| | | | | Tissue enhanced |
NOXO1 | NADPH oxidase organizer 1 | FDA approved drug targets Predicted intracellular proteins
| | | | | Tissue enhanced |
SIGLEC14 | Sialic acid binding Ig-like lectin 14 | Plasma proteins Predicted membrane proteins
| | | | | Tissue enhanced |
SIGLEC5 | Sialic acid binding Ig-like lectin 5 | CD markers Predicted membrane proteins
| | | | | Tissue enhanced |
TLR8 | Toll-like receptor 8 | CD markers Predicted membrane proteins
| | | | | Tissue enhanced |
TNFAIP6 | Tumor necrosis factor, alpha-induced protein 6 | Plasma proteins Predicted secreted proteins
| | | | | Tissue enhanced |
VCAN | Versican | Disease related genes Plasma proteins Predicted intracellular proteins Predicted secreted proteins
| | | | | Tissue enhanced |